An Ebola outbreak in the Democratic Republic of Congo has claimed more than 4,000 lives since its official detection in mid-May, with containment efforts severely hindered by armed conflict, deep public mistrust, and a critical lack of resources in unstable regions.
The epidemic, which is driven by the Bundibugyo strain of the virus, originated in the northeastern province of Ituri and has since expanded to seven provinces across the country's north and east. In North Kivu province, the Kigali-backed rebel group M23 reported on Friday that four deaths have occurred among six recorded cases in areas under its control.
Security challenges have escalated in recent days, disrupting the medical response. According to the United Nations, violent clashes between local militias in Ituri have forced more than 5,000 people to flee their homes. On Tuesday, a transit center for Ebola patients in Ituri was burned down after government soldiers entered a displacement camp, prompting residents to flee. Additionally, Congolese authorities confirmed on Wednesday that an attack on a North Kivu health facility resulted in the death of a contractor tasked with detecting Ebola cases.
International diplomatic and financial support is arriving, though challenges persist. French Foreign Minister Jean-Noel Barrot was scheduled to visit Bunia, the capital of Ituri, on Friday to demonstrate solidarity with local authorities and humanitarian workers. While France has not announced new funding, it previously allocated €13.4 million to the Ebola response between January and July. Meanwhile, the United States has pledged an additional €237 million to help curb the spread of the disease.
Healthcare workers face extreme danger in remote, impoverished regions where medical infrastructure is severely lacking. While researchers study several vaccines and treatments for the Bundibugyo strain, clinical trials have begun using the Ervebo vaccine. Frontline volunteers have received the first doses of Ervebo, which has previously proven highly effective against the Zaire strain, the most common variant of the virus.
